|
MedMira Completes Submission for World Health Organization's New Prequalification Diagnostics Programme
Building on Global Public Health Sales Channels including USAID and PAHO
HALIFAX, June 24 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF), a developer and marketer of rapid diagnostics, said today that
it has submitted the MedMira Rapid HIV Test for evaluation in the World Health
Organization's (WHO) new Prequalification Diagnostics Programme launched on
June 16, 2008. The Programme is designed to provide guidance and advice on
quality health technologies, including rapid tests for HIV, that are supplied
to people around the globe through various public health agencies including
the United Nations.
"We have been steadily building our global public health sales channels
over the past year, establishing MedMira as an approved vendor with USAID and
the Pan American Health Organization (PAHO). The WHO Programme will be another
opportunity for us to tap into tender opportunities and large scale public
health initiatives in developing nations," said Hermes Chan, President and
CEO, MedMira Inc. "We believe that the MedMira Rapid HIV Test will exceed all
of the requirements and characteristics that the WHO is seeking in the rapid
diagnostics that are being evaluated and approved under this new program."
According to the WHO guidelines, the Programme is designed to increase
access to quality diagnostics that are both affordable and appropriate for use
in resource-constrained settings such as mobile clinics in rural areas, which
have little or no access to traditional healthcare tools. The MedMira Rapid
HIV Test is built on the Company's patented rapid flow-through technology
platform, which is the product engine behind MedMira's successful line of
rapid HIV tests that have been approved in Canada, the United States, the
European Union, China, Russia, and India. The test requires no specialized
training or equipment to perform, and uses a whole blood, serum or plasma
specimen to deliver results in just three minutes. The MedMira Rapid HIV Test
has an extended shelf-life with no refrigeration required, making it ideally
suited for all types of testing environments. All of MedMira's tests are
manufactured in Canada under ISO and GMP standards.
-30-
About MedMira
MedMira is a leading developer, manufacturer, and marketer of advanced
rapid diagnostics. Built on the Company's patented rapid flow-through
technology platform, MedMira's single and multiple rapid tests provide
hospitals, labs, clinics and individuals around the world with reliable,
diagnosis for diseases such as HIV and hepatitis C in just three minutes. The
company's tests, which are sold under the Reveal(R), MiraWell(R), MiraCare(TM)
and Multiplo(TM) brands in global markets, have achieved regulatory approvals
in Canada, the United States, China, Russia, India, and the European Union.
MedMira is an approved supplier to US Agency for International Development
(USAID) and the Pan American Health Organization (PAHO).
In 2006, MedMira launched the Maple Biosciences division to develop and
commercialize diagnostic instruments based on biosensor technology platforms.
The new diagnostic solutions will enable routine laboratory tests to be
performed in a matter of minutes, increasing automation, and streamlining the
diagnosis of multiple conditions and diseases. Together MedMira and Maple
Biosciences will be leading participants in the emerging fields of
personalized medicine and molecular diagnostics. For more information visit
www.maplebio.com.
MedMira's corporate offices, R&D, and manufacturing facilities are
located in Halifax, Nova Scotia, Canada. For more information visit MedMira's
website at .
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the
company's current expectation regarding future events. Actual events could materially differ from those
projected herein and depend on a number of factors including, but not limited to, changing market conditions,
successful and timely completion of clinical studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to time in the company quarterly
filings.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy
of this statement.
Contacts:
Dr. James Smith, Investor Relations & Corporate Affairs
Tel: 902-450-1588
E-mail: ir@medmira.com
ir@medmira.com
"Reproduced with permission - MedMira"
MedMira
|
 |
